| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.93 M USD | -8.95 M USD | -13.72 M USD | -16.17 M USD | -12.70 M USD | -7.81 M USD | -2.85 M USD | -4.63 M USD | -5.99 M USD | -5.82 M USD | -8.64 M USD | -7.25 M USD |
| Depreciation & Amortization | 814000 USD | 980000 USD | 626000 USD | 244000 USD | 159000 USD | 334000 USD | 143604 USD | 109439 USD | 116454 USD | 155707 USD | 211946 USD | 377261 USD |
| Stock-Based Compensation | 8.18 M USD | 6.91 M USD | 6.08 M USD | 4.13 M USD | 2.08 M USD | 1.09 M USD | 799111 USD | 1.23 M USD | 1.25 M USD | 959585 USD | 1.68 M USD | 880765 USD |
| Capital Expenditures | 522000 USD | 275000 USD | 717000 USD | 253000 USD | 168000 USD | 41000 USD | 10190 USD | 63490 USD | 26752 USD | 101002 USD | 76883 USD | 48129 USD |
| Cash Flow from Investing | 615000 USD | -275000 USD | 8.95 M USD | -10.74 M USD | -168000 USD | -482000 USD | -160190 USD | -63490 USD | -26752 USD | -101002 USD | -76883 USD | -48129 USD |
| Cash Flow from Financing | 50.18 M USD | 6.19 M USD | 296000 USD | 409000 USD | 46.88 M USD | 22.69 M USD | 5.60 M USD | -1.49 M USD | 11.99 M USD | 3.83 M USD | 4.88 M USD | 13.03 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -24.45 M USD | -9.22 M USD | -14.44 M USD | -16.42 M USD | -12.87 M USD | -7.85 M USD | -2.86 M USD | -4.69 M USD | -6.02 M USD | -5.92 M USD | -8.71 M USD | -7.30 M USD |
ClearPoint Neuro Inc. is a global device, cell, and gene therapy-enabling company specializing in precise navigation and delivery systems to the brain and spine. It develops and commercializes platforms like the ClearPoint system for minimally invasive neurosurgical procedures under real-time MRI guidance, supporting deep brain stimulation electrode insertions, biopsies, laser catheter placements, and pharmaceutical infusions. The company offers established clinical products alongside pre-clinical development services for controlled drug and device delivery, including the SmartFlow cannula for gene therapy and the ClearPoint Prism Neuro Laser Therapy System. ClearPoint Neuro also provides the IRRAflow system for active intracranial fluid management following its acquisition of IRRAS. Engaged with over 90 neurosurgery centers and more than 60 biologics and drug delivery partners worldwide across North America, Europe, Asia, and South America, it supports healthcare professionals, researchers, and biopharma in translational research, clinical trials, and patient treatments for complex neurological disorders. Founded in 1998 and headquartered in Solana Beach, California, ClearPoint Neuro maintains a dedicated focus on the neuro space through its Global Training and Innovation Center.